The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …

Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2)
are associated with the development of many tumors. It is currently a crucial treatment for …

Innumerable people worldwide die of cancer every year, although pharmaceutical therapy
has actualized many benefits in human health. For background, anti-cancer drug …

Antibody–drug conjugates (ADCs) have provided new therapeutic options and significant
promise for patients with cancer, particularly where existing treatments are limited …

Gastric cancer (GC) is one of the most common malignant tumors worldwide. Its incidence
ranks the 5th among all malignant tumors globally, and it is the 3rd leading cause of death …

Recently, liquid biopsy based on detection of circulating nucleic acid (NA) biomarkers from
body fluids has emerged as a promising strategy for lung cancer monitoring. Considering …

Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …

Antibody-drug conjugates (ADCs) are important in active tumor-targeting therapy. However,
improving the efficiency of payload delivery to tumors without affecting the tumor-targeting …

Gastric carcinomas are among the most common cancers in Germany, with approximately
18,000 new cases per year. About 10 years ago, based on results of the Trastuzumab for …

The use of genetic testing to personalize therapeutic strategies in cancer is rapidly evolving
and thus changing the landscape of treatment of oncologic patients. The UGT1A1 gene is an …